Literature DB >> 23018442

Risk, predictors, and mortality associated with non-AIDS events in newly diagnosed HIV-infected patients: role of antiretroviral therapy.

Mar Masiá1, Sergio Padilla, Débora Álvarez, Juan C López, Ignacio Santos, Vicente Soriano, José Hernández-Quero, Jesús Santos, Cristina Tural, Julia del Amo, Félix Gutiérrez.   

Abstract

OBJECTIVE: We aimed to characterize non-AIDS events (NAEs) occurring in newly diagnosed HIV-infected patients in a contemporary cohort.
METHODS: The Cohort of the AIDS Research Network (CoRIS) is a prospective, multicenter cohort of HIV-infected adults antiretroviral naive at entry, established in 2004. We evaluated the incidence of and the mortality due to NAEs and AIDS events through October 2010. Poisson regression was used to investigate factors associated with a higher incidence of NAEs.
RESULTS: Overall, 5185 patients (13.306 person-years of follow-up), median age (interquartile range) 36 (29-43) years, participated in the study. A total of 86.5% patients had been diagnosed in 2004 or later. The incidence rate of NAEs was 28.93 per 1000 person-years [95% confidence interval (CI) 26.15-32.07], and of AIDS-defining events 25.23 per 1000 person-years (95% CI 22.60-28.16). The most common NAEs were psychiatric, hepatic, malignant, renal, and cardiovascular related. After adjustment, age, higher HIV-viral load, and lower CD4 cell count at cohort entry were associated with the occurrence of NAEs, whereas likelihood significantly decreased with sexual transmission and higher educational level. Additionally, antiretroviral therapy was inversely associated with the development of some NAEs, specifically of psychiatric [incidence rate ratio (95% CI) 0.54 (0.30-0.96)] and renal-related [incidence rate ratio (95% CI) 0.31 (0.13-0.72)] events. One hundred and seventy-three (3.33%) patients died during the study period. NAEs contributed to 28.9% of all deaths, with an incidence rate (95% CI) of 3.75 (2.84-4.94) per 1000 person-years.
CONCLUSION: In patients newly diagnosed with HIV infection, NAEs are a significant cause of morbidity and mortality. Our results suggest a protective effect of antiretroviral therapy in the occurrence of NAEs, in particular of psychiatric and renal-related events.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23018442     DOI: 10.1097/QAD.0b013e32835a1156

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  16 in total

1.  Transgender Women Living with HIV Frequently Take Antiretroviral Therapy and/or Feminizing Hormone Therapy Differently Than Prescribed Due to Drug-Drug Interaction Concerns.

Authors:  Hannan M Braun; Jury Candelario; Courtney L Hanlon; Eddy R Segura; Jesse L Clark; Judith S Currier; Jordan E Lake
Journal:  LGBT Health       Date:  2017-09-06       Impact factor: 4.151

2.  Delayed-type hypersensitivity and hepatitis B vaccine responses, in vivo markers of cellular and humoral immune function, and the risk of AIDS or death.

Authors:  Shane B Patterson; Michael L Landrum; Jason F Okulicz
Journal:  Vaccine       Date:  2014-04-29       Impact factor: 3.641

3.  Trends in hospital deaths among human immunodeficiency virus-infected patients during the antiretroviral therapy era, 1995 to 2011.

Authors:  Annie Cowell; Sheela V Shenoi; Tassos C Kyriakides; Gerald Friedland; Lydia Aoun Barakat
Journal:  J Hosp Med       Date:  2015-06-30       Impact factor: 2.960

Review 4.  The Fat of the Matter: Obesity and Visceral Adiposity in Treated HIV Infection.

Authors:  Jordan E Lake
Journal:  Curr HIV/AIDS Rep       Date:  2017-12       Impact factor: 5.071

5.  Trans women have worse cardiovascular biomarker profiles than cisgender men independent of hormone use and HIV serostatus.

Authors:  Jordan E Lake; Ruibin Wang; Benjamin W Barrett; Emily Bowman; Ana N Hyatt; Paula Debroy; Jury Candelario; Linda Teplin; Kaitlin Bodnar; Heather McKay; Michael Plankey; Todd T Brown; Nicholas Funderburg; Judith S Currier
Journal:  AIDS       Date:  2022-08-10       Impact factor: 4.632

6.  Differential levels of soluble inflammatory markers by human immunodeficiency virus controller status and demographics.

Authors:  Jonathan Z Li; Kelly B Arnold; Janet Lo; Anne-Sophie Dugast; Jill Plants; Heather J Ribaudo; Kevin Cesa; Andrea Heisey; Daniel R Kuritzkes; Douglas A Lauffenburger; Galit Alter; Alan Landay; Steven Grinspoon; Florencia Pereyra
Journal:  Open Forum Infect Dis       Date:  2015-01-13       Impact factor: 3.835

7.  Serious Non-AIDS events: Immunopathogenesis and interventional strategies.

Authors:  Denise C Hsu; Irini Sereti; Jintanat Ananworanich
Journal:  AIDS Res Ther       Date:  2013-12-13       Impact factor: 2.250

8.  Coinfection with human herpesvirus 8 is associated with persistent inflammation and immune activation in virologically suppressed HIV-infected patients.

Authors:  Mar Masiá; Catalina Robledano; Victoria Ortiz de la Tabla; Pedro Antequera; Blanca Lumbreras; Ildefonso Hernández; Félix Gutiérrez
Journal:  PLoS One       Date:  2014-08-18       Impact factor: 3.240

9.  Oral Glucose Tolerance Testing identifies HIV+ infected women with Diabetes Mellitus (DM) not captured by standard DM definition.

Authors:  Sophie Seang; Jordan E Lake; Fang Tian; Kathryn Anastos; Mardge H Cohen; Phyllis C Tien
Journal:  J AIDS Clin Res       Date:  2016-02-20

10.  Oxidative Stress Predicts All-Cause Mortality in HIV-Infected Patients.

Authors:  Mar Masiá; Sergio Padilla; Marta Fernández; Carmen Rodríguez; Ana Moreno; Jose A Oteo; Antonio Antela; Santiago Moreno; Julia Del Amo; Félix Gutiérrez
Journal:  PLoS One       Date:  2016-04-25       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.